Contract manufacturer Angel Biotechnology Holdings PLC (AIM: ABH) said it signed a contract with ReNeuron Group PLC (AIM: RENE) to perform work to further develop and manufacture clinical-grade lots of a second-generation formulation of ReNeuron's CTX stem cell line, for subsequent pre-clinical and clinical applications.
The value of the contract was not disclosed.
As ReNeuron's manufacturing partner, Angel will be manufacturing the stem cell clinical product for their previously announced first-in-man Phase I clinical trial for stroke,
The CTX cell line forms the basis of ReNeuron's ReN001 therapy for stroke and its ReN009 therapy for peripheral artery disease.